Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection

Lack of biomarkers for treatment monitoring is listed among the main requirements for next generation assays, as identified globally among tuberculosis (TB) researchers. In this study, we evaluated in a low TB endemic country such as Italy, the effect of preventive therapy on the results obtained in...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Scientific reports Ročník 8; číslo 1; s. 15626 - 11
Hlavní autori: Petruccioli, Elisa, Chiacchio, Teresa, Vanini, Valentina, Cuzzi, Gilda, Codecasa, Luigi Ruffo, Ferrarese, Maurizio, Schininà, Vincenzo, Palmieri, Fabrizio, Ippolito, Giuseppe, Goletti, Delia
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London Nature Publishing Group UK 23.10.2018
Nature Publishing Group
Predmet:
13
13/21
631/250/255/1856
692/308/575
Antigens
Diagnosis
Humanities and Social Sciences
multidisciplinary
Patients
Peptides
Science
Science (multidisciplinary)
Tuberculosis
γ-Interferon
Microbiological Diagnosis
Uncertain Zone
Latent TB Infection (LTBI)
Relapse Criteria
Preventive Intervention Effects
ISSN:2045-2322, 2045-2322
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Lack of biomarkers for treatment monitoring is listed among the main requirements for next generation assays, as identified globally among tuberculosis (TB) researchers. In this study, we evaluated in a low TB endemic country such as Italy, the effect of preventive therapy on the results obtained in the QuantiFERON TB Plus (QFT-Plus), in a cohort of subjects with latent TB infection (LTBI) and active TB. We found that TB therapy significantly decreased IFN-γ values and number of responders to TB1- and TB2- peptides stimulation in both LTBI and active TB patients. Stratifying LTBI subjects according to the type of preventive TB therapy used, we found that INH treatment but not INH and RIF significantly decreased IFN-γ production. Stratifying the active TB patients according the microbiological status, we found that TB therapy significantly decreased IFN-γ response to antigen present in QFT-Plus test in patients with clinical diagnosis compared to those with a microbiological diagnosis. In conclusions, we demonstrated that TB therapy decreases IFN-γ level in response to antigen present in QFT-Plus test in LTBI and active TB patients. Future studies are needed to better characterize Mtb-specifc response as a potential marker for monitoring TB therapy and preventive treatment effects.
AbstractList Lack of biomarkers for treatment monitoring is listed among the main requirements for next generation assays, as identified globally among tuberculosis (TB) researchers. In this study, we evaluated in a low TB endemic country such as Italy, the effect of preventive therapy on the results obtained in the QuantiFERON TB Plus (QFT-Plus), in a cohort of subjects with latent TB infection (LTBI) and active TB. We found that TB therapy significantly decreased IFN-γ values and number of responders to TB1- and TB2- peptides stimulation in both LTBI and active TB patients. Stratifying LTBI subjects according to the type of preventive TB therapy used, we found that INH treatment but not INH and RIF significantly decreased IFN-γ production. Stratifying the active TB patients according the microbiological status, we found that TB therapy significantly decreased IFN-γ response to antigen present in QFT-Plus test in patients with clinical diagnosis compared to those with a microbiological diagnosis. In conclusions, we demonstrated that TB therapy decreases IFN-γ level in response to antigen present in QFT-Plus test in LTBI and active TB patients. Future studies are needed to better characterize Mtb-specifc response as a potential marker for monitoring TB therapy and preventive treatment effects.
Lack of biomarkers for treatment monitoring is listed among the main requirements for next generation assays, as identified globally among tuberculosis (TB) researchers. In this study, we evaluated in a low TB endemic country such as Italy, the effect of preventive therapy on the results obtained in the QuantiFERON TB Plus (QFT-Plus), in a cohort of subjects with latent TB infection (LTBI) and active TB. We found that TB therapy significantly decreased IFN-γ values and number of responders to TB1- and TB2- peptides stimulation in both LTBI and active TB patients. Stratifying LTBI subjects according to the type of preventive TB therapy used, we found that INH treatment but not INH and RIF significantly decreased IFN-γ production. Stratifying the active TB patients according the microbiological status, we found that TB therapy significantly decreased IFN-γ response to antigen present in QFT-Plus test in patients with clinical diagnosis compared to those with a microbiological diagnosis. In conclusions, we demonstrated that TB therapy decreases IFN-γ level in response to antigen present in QFT-Plus test in LTBI and active TB patients. Future studies are needed to better characterize Mtb-specifc response as a potential marker for monitoring TB therapy and preventive treatment effects.Lack of biomarkers for treatment monitoring is listed among the main requirements for next generation assays, as identified globally among tuberculosis (TB) researchers. In this study, we evaluated in a low TB endemic country such as Italy, the effect of preventive therapy on the results obtained in the QuantiFERON TB Plus (QFT-Plus), in a cohort of subjects with latent TB infection (LTBI) and active TB. We found that TB therapy significantly decreased IFN-γ values and number of responders to TB1- and TB2- peptides stimulation in both LTBI and active TB patients. Stratifying LTBI subjects according to the type of preventive TB therapy used, we found that INH treatment but not INH and RIF significantly decreased IFN-γ production. Stratifying the active TB patients according the microbiological status, we found that TB therapy significantly decreased IFN-γ response to antigen present in QFT-Plus test in patients with clinical diagnosis compared to those with a microbiological diagnosis. In conclusions, we demonstrated that TB therapy decreases IFN-γ level in response to antigen present in QFT-Plus test in LTBI and active TB patients. Future studies are needed to better characterize Mtb-specifc response as a potential marker for monitoring TB therapy and preventive treatment effects.
ArticleNumber 15626
Author Ferrarese, Maurizio
Palmieri, Fabrizio
Ippolito, Giuseppe
Vanini, Valentina
Petruccioli, Elisa
Goletti, Delia
Schininà, Vincenzo
Chiacchio, Teresa
Cuzzi, Gilda
Codecasa, Luigi Ruffo
Author_xml – sequence: 1
  givenname: Elisa
  surname: Petruccioli
  fullname: Petruccioli, Elisa
  organization: Translational Research Unit National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS
– sequence: 2
  givenname: Teresa
  surname: Chiacchio
  fullname: Chiacchio, Teresa
  organization: Translational Research Unit National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS
– sequence: 3
  givenname: Valentina
  surname: Vanini
  fullname: Vanini, Valentina
  organization: Translational Research Unit National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS
– sequence: 4
  givenname: Gilda
  surname: Cuzzi
  fullname: Cuzzi, Gilda
  organization: Translational Research Unit National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS
– sequence: 5
  givenname: Luigi Ruffo
  orcidid: 0000-0001-6825-2050
  surname: Codecasa
  fullname: Codecasa, Luigi Ruffo
  organization: Regional TB Reference Centre, Istituto Villa Marelli, Ospedale Niguarda
– sequence: 6
  givenname: Maurizio
  surname: Ferrarese
  fullname: Ferrarese, Maurizio
  organization: Regional TB Reference Centre, Istituto Villa Marelli, Ospedale Niguarda
– sequence: 7
  givenname: Vincenzo
  surname: Schininà
  fullname: Schininà, Vincenzo
  organization: Clinical Department National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
– sequence: 8
  givenname: Fabrizio
  surname: Palmieri
  fullname: Palmieri, Fabrizio
  organization: Clinical Department National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
– sequence: 9
  givenname: Giuseppe
  surname: Ippolito
  fullname: Ippolito, Giuseppe
  organization: Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
– sequence: 10
  givenname: Delia
  surname: Goletti
  fullname: Goletti, Delia
  email: delia.goletti@inmi.it
  organization: Translational Research Unit National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30353115$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1rVDEUhoNU7If9Ay4k4MbN1Xzem7sRpNQqFFTQdchkTjopd5Ixye3Qf-8Zp9baRbNJSJ73zTnnPSYHKScg5BVn7ziT5n1VXI-mY9x0Uhqhu-0zciSY0p2QQhw8OB-S01qvGS4tRsXHF-RQMqkl5_qIrM5DAN9oDrStoLjNLc2Jfp9dajFAyan7Ns2VFqibnCrQmOjGtQipVbqNbUWdb_EGqEtLOrmG97TNCyh-nnKNFfmdfczpJXke3FTh9G4_IT8_nf84-9xdfr34cvbxsvNqUK1zKqjQj8z4wYseloYZB4MyXCq9wCWGhebjqF1vRPBDGPwY1Nj3XHMve-bkCfmw993MizUsPVZU3GQ3Ja5dubXZRfv_S4ore5VvbI-2kms0eHtnUPKvGWqz61g9TJNLkOdqBRc4Oxxuj-ibR-h1nkvC9naUUhozkki9fljRfSl_Q0BA7AFfcq0Fwj3Cmd2FbfdhWwzb_gnbblFkHol8bG43aewqTk9L5V5a8Z90BeVf2U-ofgN1b8Au
CitedBy_id crossref_primary_10_1097_INF_0000000000004058
crossref_primary_10_1016_j_jinf_2019_08_018
crossref_primary_10_1016_j_jinf_2020_02_009
crossref_primary_10_1038_s41598_021_93059_1
crossref_primary_10_1111_apm_13025
crossref_primary_10_1080_09273948_2022_2027459
crossref_primary_10_1128_spectrum_02445_21
crossref_primary_10_1371_journal_pone_0234700
crossref_primary_10_3390_pharmaceutics15102409
crossref_primary_10_1016_j_ijid_2019_11_023
crossref_primary_10_1093_clinchem_hvad220
crossref_primary_10_3389_fimmu_2024_1484143
crossref_primary_10_3389_fimmu_2020_616450
crossref_primary_10_3390_microorganisms11030743
crossref_primary_10_1007_s15010_020_01541_1
crossref_primary_10_1136_bmjophth_2020_000663
crossref_primary_10_1016_j_intimp_2024_112115
crossref_primary_10_1371_journal_pone_0240250
crossref_primary_10_1016_j_jinf_2024_106295
crossref_primary_10_1007_s00005_020_00568_4
crossref_primary_10_1016_j_jinf_2019_04_010
crossref_primary_10_1183_16000617_0044_2022
crossref_primary_10_4103_ijmy_ijmy_132_21
crossref_primary_10_3389_fimmu_2022_984098
crossref_primary_10_1016_j_cmi_2020_02_009
crossref_primary_10_3389_fimmu_2021_716857
Cites_doi 10.1093/cid/ciu795
10.1183/13993003.01245-2015
10.1016/j.tube.2017.06.002
10.1164/rccm.201203-0430OC
10.1183/13993003.00510-2016
10.1128/JCM.02498-16
10.4081/idr.2016.6568
10.1093/infdis/jiu821
10.1183/13993003.02033-2015
10.1016/j.tube.2017.11.014
10.1016/j.diagmicrobio.2016.06.007
10.1371/journal.pone.0193589
10.1016/j.imlet.2018.04.001
10.1016/j.jinf.2016.09.008
10.1111/resp.13272
10.1164/rccm.201107-1355OC
10.1183/13993003.01179-2015
10.4049/jimmunol.1701737
10.1016/j.jinf.2013.02.004
10.1183/13993003.01976-2016
10.1164/rccm.200306-837OC
10.1002/eji.201243262
10.1016/j.jinf.2014.06.009
10.1016/j.jiac.2017.09.012
10.1183/09031936.00214014
10.1371/journal.pone.0183846
10.1183/13993003.01012-2016
10.4049/jimmunol.1101122
10.1371/journal.pone.0094949
10.1183/13993003.00153-2018
10.5588/ijtld.16.0342
10.1155/2015/589471
10.1164/rccm.201704-0817OC
ContentType Journal Article
Copyright The Author(s) 2018
2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2018
– notice: 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.1038/s41598-018-33825-w
DatabaseName Springer Nature Link
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef

PubMed
Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 11
ExternalDocumentID PMC6199315
30353115
10_1038_s41598_018_33825_w
Genre Journal Article
GrantInformation_xml – fundername: EC | Horizon 2020 (European Union Framework Programme for Research and Innovation)
  grantid: 643381-TBVAC2020- H2020-PHC-2014-2015; 643381-TBVAC2020- H2020-PHC-2014-2015
  funderid: https://doi.org/10.13039/501100007601
– fundername: National Institutes of Health of USA : NIH 1R21AI127133-01 Italian Ministry of Health: “Ricerca Corrente”
– fundername: EC | Horizon 2020 (European Union Framework Programme for Research and Innovation)
  grantid: 643381-TBVAC2020- H2020-PHC-2014-2015
– fundername: ;
– fundername: ;
  grantid: 643381-TBVAC2020- H2020-PHC-2014-2015; 643381-TBVAC2020- H2020-PHC-2014-2015
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
EJD
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IPNFZ
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RIG
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFFHD
AFPKN
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
NPM
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c474t-a4f4f6908c7c26ed808ae7481345bbbb27b51995a682fc7f7c9f4966151c360a3
IEDL.DBID M7P
ISICitedReferencesCount 26
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000448049400023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2045-2322
IngestDate Tue Nov 04 01:58:59 EST 2025
Fri Sep 05 13:33:31 EDT 2025
Tue Oct 07 07:32:05 EDT 2025
Wed Feb 19 02:42:39 EST 2025
Tue Nov 18 22:35:37 EST 2025
Sat Nov 29 02:11:29 EST 2025
Fri Feb 21 02:38:52 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Microbiological Diagnosis
Uncertain Zone
Latent TB Infection (LTBI)
Relapse Criteria
Preventive Intervention Effects
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c474t-a4f4f6908c7c26ed808ae7481345bbbb27b51995a682fc7f7c9f4966151c360a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-6825-2050
OpenAccessLink https://www.proquest.com/docview/2124454153?pq-origsite=%requestingapplication%
PMID 30353115
PQID 2124454153
PQPubID 2041939
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6199315
proquest_miscellaneous_2125310456
proquest_journals_2124454153
pubmed_primary_30353115
crossref_primary_10_1038_s41598_018_33825_w
crossref_citationtrail_10_1038_s41598_018_33825_w
springer_journals_10_1038_s41598_018_33825_w
PublicationCentury 2000
PublicationDate 2018-10-23
PublicationDateYYYYMMDD 2018-10-23
PublicationDate_xml – month: 10
  year: 2018
  text: 2018-10-23
  day: 23
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2018
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References DayCLFunctional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial loadJ. Immunol.2011187222222321:CAS:528:DC%2BC3MXhtVGmsLnP10.4049/jimmunol.1101122
KamadaArisuAmishimaMasaruQuantiFERON-TB®Gold Plus as a potential tuberculosis treatment monitoring toolEuropean Respiratory Journal2017493160197610.1183/13993003.01976-2016
QuantiFERON®-TB Gold Plus, ELISA Package Insert, QUIAGEN, http://www.quantiferon.com/irm/content/PI/QFT/PLUS/2PK-Elisa/UK.pdf.
PetroneLBlood and urine inducible protein 10 as potential markers of disease activityInt. J. Tuberc. Lung Dis.201620155415611:STN:280:DC%2BC2srpt1Witg%3D%3D10.5588/ijtld.16.0342
ChiacchioTImpact of antiretroviral and tuberculosis therapies on CD4(+) and CD8(+) HIV/M. tuberculosis-specific T-cell in co-infected subjectsImmunol. Lett.201819833431:CAS:528:DC%2BC1cXns1CjsL4%3D10.1016/j.imlet.2018.04.001
DayCLPatients with tuberculosis disease have Mycobacterium tuberculosis-specific CD8 T cells with a pro-apoptotic phenotype and impaired proliferative capacity, which is not restored following treatmentPLoS One20149e949492014PLoSO...994949D10.1371/journal.pone.0094949
ChiacchioTPolyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patientsJ. Infect.20146953354510.1016/j.jinf.2014.06.009
LewinsohnDAMycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cellsAm. J. Respir. Crit. Care Med.20031681346135210.1164/rccm.200306-837OC
BarcelliniLFirst independent evaluation of QuantiFERON-TB Plus performanceEur. Respir. J.2016471587159010.1183/13993003.02033-2015
IgariHLymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent tuberculosis infection in rheumatoid arthritisJ. Infect. Chemother.20182411011610.1016/j.jiac.2017.09.012
NemesEOptimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis InfectionAm. J. Respir. Crit. Care Med.201719663864810.1164/rccm.201704-0817OC
MazurekGHUpdated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010MMWR Recomm Rep.20105912520577159
PetruccioliEFirst characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB PlusJ. Infect.20167358859710.1016/j.jinf.2016.09.008
PetruccioliEAnalytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosisTuberculosis (Edinb)201710638431:CAS:528:DC%2BC2sXhtFams77I10.1016/j.tube.2017.06.002
MoonHWEvaluation of QuantiFERON-TB Gold-Plus in Health Care Workers in a Low-Incidence SettingJ. Clin. Microbiol.2017551650165710.1128/JCM.02498-16
LancioniCCD8+ T cells provide an immunologic signature of tuberculosis in young childrenAm. J. Respir. Crit. Care Med.20121852062121:CAS:528:DC%2BC38XislWgtr8%3D10.1164/rccm.201107-1355OC
MatteelliANumbers needed to treat to prevent tuberculosisEur. Respir. J.2015461838183910.1183/13993003.01179-2015
PetroneLBlood or Urine IP-10 Cannot Discriminate between Active Tuberculosis and Respiratory Diseases Different from Tuberculosis inChildrenBiomed. Res. Int.2015201558947110.1155/2015/589471
RozotVMycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active diseaseEur. J. Immunol.201343156815771:CAS:528:DC%2BC3sXpvVCjs7g%3D10.1002/eji.201243262
GetahunHManagement of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countriesEur. Respir. J.201546156315761:CAS:528:DC%2BC28XntFWjtLs%3D10.1183/13993003.01245-2015
ChiacchioTImmune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infectionPLoS One201712e018384610.1371/journal.pone.0183846
Konig WallesJPerformance of QuantiFERON-TB Gold Plus for detection of latent tuberculosis infection in pregnant women living in a tuberculosis- and HIV-endemic settingPLoS One201813e019358910.1371/journal.pone.0193589
LonnrothKTowards tuberculosis elimination: an action framework for low-incidence countriesEur. Respir. J.201545928952257926304391660
BarcelliniLFirst evaluation of QuantiFERON-TB Gold Plus performance in contact screeningEur. Respir. J.201648141114191:CAS:528:DC%2BC1cXjtFGr10.1183/13993003.00510-2016
PetruccioliEUse of several immunological markers to model the probability of active tuberculosisDiagn. Microbiol. Infect. Dis.20168616917110.1016/j.diagmicrobio.2016.06.007
GolettiDPetruccioliEJoostenSAOttenhoffTHTuberculosis Biomarkers: From Diagnosis to ProtectionInfect. Dis. Rep.20168656810.4081/idr.2016.6568
GolettiDLeeMRWangJYWalterNOttenhoffTHMUpdate on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from diseaseRespirology20182345546610.1111/resp.13272
DenkingerCMDefining the needs for next generation assays for tuberculosisJ. Infect. Dis.2015211Suppl 2S293810.1093/infdis/jiu821
PetruccioliEIFNgamma/TNFalpha specific-cells and effector memory phenotype associate with active tuberculosisJ. Infect.20136647548610.1016/j.jinf.2013.02.004
RozotVCombined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosisClin. Infect. Dis.2015604324371:CAS:528:DC%2BC28XhvFWlsLfE10.1093/cid/ciu795
MusvosviMunyaradziDuffyDarraghFilanderElizabethAfricaHadnMabweSimbarasheJaxaLungisaBilekNicoleLlibreAlbaRouillyVincentHatherillMarkAlbertMatthewScribaThomas J.NemesElisaT-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translationEuropean Respiratory Journal2018513180015310.1183/13993003.00153-2018
MetcalfeJZTest variability of the QuantiFERON-TB gold in-tube assay in clinical practiceAm. J. Respir. Crit. Care Med.20131872062111:CAS:528:DC%2BC3sXjsVSqs7k%3D10.1164/rccm.201203-0430OC
PetruccioliECorrelates of tuberculosis risk: predictive biomarkers for progression to active tuberculosisEur. Respir. J.201648175117631:CAS:528:DC%2BC1cXlvVyn10.1183/13993003.01012-2016
WHO. Global tuberculosis report 2017, www.who.int/tb/publications/global_report/en/ (2017).
PaiMT-cell assay conversions and reversions among household contacts of tuberculosis patients in rural IndiaInt. J. Tuberc. Lung Dis.20091384921:STN:280:DC%2BD1M%2FksV2lsg%3D%3D191058842951989
PietermanEDA multicentre verification study of the QuantiFERON((R))-TB Gold Plus assayTuberculosis (Edinb)20181081361421:CAS:528:DC%2BC2sXhvFCrsLzI10.1016/j.tube.2017.11.014
WhatneyWEA High Throughput Whole Blood Assay for Analysis of Multiple Antigen-Specific T Cell Responses in Human Mycobacterium tuberculosis InfectionJ. Immunol.2018200300830191:CAS:528:DC%2BC1cXntFOmt7Y%3D10.4049/jimmunol.1701737
E Petruccioli (33825_CR28) 2016; 73
C Lancioni (33825_CR24) 2012; 185
L Barcellini (33825_CR26) 2016; 47
HW Moon (33825_CR37) 2017; 55
JZ Metcalfe (33825_CR33) 2013; 187
D Goletti (33825_CR5) 2018; 23
V Rozot (33825_CR17) 2015; 60
J Konig Walles (33825_CR16) 2018; 13
E Petruccioli (33825_CR12) 2013; 66
E Petruccioli (33825_CR13) 2016; 48
V Rozot (33825_CR25) 2013; 43
E Petruccioli (33825_CR9) 2016; 86
E Nemes (33825_CR32) 2017; 196
WE Whatney (33825_CR14) 2018; 200
CL Day (33825_CR19) 2011; 187
DA Lewinsohn (33825_CR21) 2003; 168
E Petruccioli (33825_CR29) 2017; 106
D Goletti (33825_CR6) 2016; 8
T Chiacchio (33825_CR23) 2014; 69
CL Day (33825_CR20) 2014; 9
CM Denkinger (33825_CR7) 2015; 211
GH Mazurek (33825_CR31) 2010; 59
L Barcellini (33825_CR27) 2016; 48
ED Pieterman (33825_CR35) 2018; 108
Arisu Kamada (33825_CR36) 2017; 49
H Igari (33825_CR15) 2018; 24
H Getahun (33825_CR3) 2015; 46
K Lonnroth (33825_CR4) 2015; 45
L Petrone (33825_CR11) 2015; 2015
L Petrone (33825_CR10) 2016; 20
T Chiacchio (33825_CR8) 2017; 12
M Pai (33825_CR34) 2009; 13
T Chiacchio (33825_CR22) 2018; 198
33825_CR30
33825_CR1
A Matteelli (33825_CR2) 2015; 46
Munyaradzi Musvosvi (33825_CR18) 2018; 51
26621888 - Eur Respir J. 2015 Dec;46(6):1838-9
29523314 - Tuberculosis (Edinb). 2018 Jan;108:136-142
23103734 - Am J Respir Crit Care Med. 2013 Jan 15;187(2):206-11
26405286 - Eur Respir J. 2015 Dec;46(6):1563-76
27836953 - Eur Respir J. 2016 Dec;48(6):1751-1763
28331040 - Eur Respir J. 2017 Mar 22;49(3)
27717779 - J Infect. 2016 Dec;73(6):588-597
24975174 - J Infect. 2014 Dec;69(6):533-45
25792630 - Eur Respir J. 2015 Apr;45(4):928-52
28737960 - Am J Respir Crit Care Med. 2017 Sep 1;196(5):638-648
28298455 - J Clin Microbiol. 2017 Jun;55(6):1650-1657
29054459 - J Infect Chemother. 2018 Feb;24(2):110-116
25362202 - Clin Infect Dis. 2015 Feb 1;60(3):432-7
29635002 - Immunol Lett. 2018 Jun;198:33-43
28837654 - PLoS One. 2017 Aug 24;12(8):e0183846
23456989 - Eur J Immunol. 2013 Jun;43(6):1568-77
21775682 - J Immunol. 2011 Sep 1;187(5):2222-32
29540577 - J Immunol. 2018 Apr 15;200(8):3008-3019
20577159 - MMWR Recomm Rep. 2010 Jun 25;59(RR-5):1-25
26869677 - Eur Respir J. 2016 May;47(5):1587-90
19105884 - Int J Tuberc Lung Dis. 2009 Jan;13(1):84-92
27403267 - Infect Dis Rep. 2016 Jun 24;8(2):6568
26346028 - Biomed Res Int. 2015;2015:589471
24740417 - PLoS One. 2014 Apr 16;9(4):e94949
27776600 - Int J Tuberc Lung Dis. 2016 Nov;20(11):1554-1561
29567725 - Eur Respir J. 2018 Mar 22;51(3):null
23462597 - J Infect. 2013 Jun;66(6):475-86
12969871 - Am J Respir Crit Care Med. 2003 Dec 1;168(11):1346-52
29457312 - Respirology. 2018 May;23(5):455-466
29617458 - PLoS One. 2018 Apr 4;13(4):e0193589
25765104 - J Infect Dis. 2015 Apr 1;211 Suppl 2:S29-38
27390280 - Eur Respir J. 2016 Nov;48(5):1411-1419
27431433 - Diagn Microbiol Infect Dis. 2016 Oct;86(2):169-71
28802403 - Tuberculosis (Edinb). 2017 Sep;106:38-43
22071329 - Am J Respir Crit Care Med. 2012 Jan 15;185(2):206-12
References_xml – reference: RozotVMycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active diseaseEur. J. Immunol.201343156815771:CAS:528:DC%2BC3sXpvVCjs7g%3D10.1002/eji.201243262
– reference: MatteelliANumbers needed to treat to prevent tuberculosisEur. Respir. J.2015461838183910.1183/13993003.01179-2015
– reference: PetruccioliEFirst characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB PlusJ. Infect.20167358859710.1016/j.jinf.2016.09.008
– reference: IgariHLymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent tuberculosis infection in rheumatoid arthritisJ. Infect. Chemother.20182411011610.1016/j.jiac.2017.09.012
– reference: NemesEOptimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis InfectionAm. J. Respir. Crit. Care Med.201719663864810.1164/rccm.201704-0817OC
– reference: PietermanEDA multicentre verification study of the QuantiFERON((R))-TB Gold Plus assayTuberculosis (Edinb)20181081361421:CAS:528:DC%2BC2sXhvFCrsLzI10.1016/j.tube.2017.11.014
– reference: LancioniCCD8+ T cells provide an immunologic signature of tuberculosis in young childrenAm. J. Respir. Crit. Care Med.20121852062121:CAS:528:DC%2BC38XislWgtr8%3D10.1164/rccm.201107-1355OC
– reference: WHO. Global tuberculosis report 2017, www.who.int/tb/publications/global_report/en/ (2017).
– reference: BarcelliniLFirst evaluation of QuantiFERON-TB Gold Plus performance in contact screeningEur. Respir. J.201648141114191:CAS:528:DC%2BC1cXjtFGr10.1183/13993003.00510-2016
– reference: BarcelliniLFirst independent evaluation of QuantiFERON-TB Plus performanceEur. Respir. J.2016471587159010.1183/13993003.02033-2015
– reference: Konig WallesJPerformance of QuantiFERON-TB Gold Plus for detection of latent tuberculosis infection in pregnant women living in a tuberculosis- and HIV-endemic settingPLoS One201813e019358910.1371/journal.pone.0193589
– reference: GolettiDLeeMRWangJYWalterNOttenhoffTHMUpdate on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from diseaseRespirology20182345546610.1111/resp.13272
– reference: ChiacchioTPolyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patientsJ. Infect.20146953354510.1016/j.jinf.2014.06.009
– reference: PetroneLBlood or Urine IP-10 Cannot Discriminate between Active Tuberculosis and Respiratory Diseases Different from Tuberculosis inChildrenBiomed. Res. Int.2015201558947110.1155/2015/589471
– reference: MoonHWEvaluation of QuantiFERON-TB Gold-Plus in Health Care Workers in a Low-Incidence SettingJ. Clin. Microbiol.2017551650165710.1128/JCM.02498-16
– reference: DenkingerCMDefining the needs for next generation assays for tuberculosisJ. Infect. Dis.2015211Suppl 2S293810.1093/infdis/jiu821
– reference: DayCLPatients with tuberculosis disease have Mycobacterium tuberculosis-specific CD8 T cells with a pro-apoptotic phenotype and impaired proliferative capacity, which is not restored following treatmentPLoS One20149e949492014PLoSO...994949D10.1371/journal.pone.0094949
– reference: PetruccioliEUse of several immunological markers to model the probability of active tuberculosisDiagn. Microbiol. Infect. Dis.20168616917110.1016/j.diagmicrobio.2016.06.007
– reference: QuantiFERON®-TB Gold Plus, ELISA Package Insert, QUIAGEN, http://www.quantiferon.com/irm/content/PI/QFT/PLUS/2PK-Elisa/UK.pdf.
– reference: DayCLFunctional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial loadJ. Immunol.2011187222222321:CAS:528:DC%2BC3MXhtVGmsLnP10.4049/jimmunol.1101122
– reference: PetruccioliECorrelates of tuberculosis risk: predictive biomarkers for progression to active tuberculosisEur. Respir. J.201648175117631:CAS:528:DC%2BC1cXlvVyn10.1183/13993003.01012-2016
– reference: WhatneyWEA High Throughput Whole Blood Assay for Analysis of Multiple Antigen-Specific T Cell Responses in Human Mycobacterium tuberculosis InfectionJ. Immunol.2018200300830191:CAS:528:DC%2BC1cXntFOmt7Y%3D10.4049/jimmunol.1701737
– reference: PetroneLBlood and urine inducible protein 10 as potential markers of disease activityInt. J. Tuberc. Lung Dis.201620155415611:STN:280:DC%2BC2srpt1Witg%3D%3D10.5588/ijtld.16.0342
– reference: RozotVCombined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosisClin. Infect. Dis.2015604324371:CAS:528:DC%2BC28XhvFWlsLfE10.1093/cid/ciu795
– reference: GetahunHManagement of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countriesEur. Respir. J.201546156315761:CAS:528:DC%2BC28XntFWjtLs%3D10.1183/13993003.01245-2015
– reference: KamadaArisuAmishimaMasaruQuantiFERON-TB®Gold Plus as a potential tuberculosis treatment monitoring toolEuropean Respiratory Journal2017493160197610.1183/13993003.01976-2016
– reference: LewinsohnDAMycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cellsAm. J. Respir. Crit. Care Med.20031681346135210.1164/rccm.200306-837OC
– reference: ChiacchioTImpact of antiretroviral and tuberculosis therapies on CD4(+) and CD8(+) HIV/M. tuberculosis-specific T-cell in co-infected subjectsImmunol. Lett.201819833431:CAS:528:DC%2BC1cXns1CjsL4%3D10.1016/j.imlet.2018.04.001
– reference: LonnrothKTowards tuberculosis elimination: an action framework for low-incidence countriesEur. Respir. J.201545928952257926304391660
– reference: MetcalfeJZTest variability of the QuantiFERON-TB gold in-tube assay in clinical practiceAm. J. Respir. Crit. Care Med.20131872062111:CAS:528:DC%2BC3sXjsVSqs7k%3D10.1164/rccm.201203-0430OC
– reference: MusvosviMunyaradziDuffyDarraghFilanderElizabethAfricaHadnMabweSimbarasheJaxaLungisaBilekNicoleLlibreAlbaRouillyVincentHatherillMarkAlbertMatthewScribaThomas J.NemesElisaT-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translationEuropean Respiratory Journal2018513180015310.1183/13993003.00153-2018
– reference: MazurekGHUpdated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010MMWR Recomm Rep.20105912520577159
– reference: GolettiDPetruccioliEJoostenSAOttenhoffTHTuberculosis Biomarkers: From Diagnosis to ProtectionInfect. Dis. Rep.20168656810.4081/idr.2016.6568
– reference: PetruccioliEIFNgamma/TNFalpha specific-cells and effector memory phenotype associate with active tuberculosisJ. Infect.20136647548610.1016/j.jinf.2013.02.004
– reference: PaiMT-cell assay conversions and reversions among household contacts of tuberculosis patients in rural IndiaInt. J. Tuberc. Lung Dis.20091384921:STN:280:DC%2BD1M%2FksV2lsg%3D%3D191058842951989
– reference: PetruccioliEAnalytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosisTuberculosis (Edinb)201710638431:CAS:528:DC%2BC2sXhtFams77I10.1016/j.tube.2017.06.002
– reference: ChiacchioTImmune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infectionPLoS One201712e018384610.1371/journal.pone.0183846
– volume: 60
  start-page: 432
  year: 2015
  ident: 33825_CR17
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciu795
– volume: 46
  start-page: 1563
  year: 2015
  ident: 33825_CR3
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.01245-2015
– volume: 106
  start-page: 38
  year: 2017
  ident: 33825_CR29
  publication-title: Tuberculosis (Edinb)
  doi: 10.1016/j.tube.2017.06.002
– volume: 187
  start-page: 206
  year: 2013
  ident: 33825_CR33
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/rccm.201203-0430OC
– volume: 13
  start-page: 84
  year: 2009
  ident: 33825_CR34
  publication-title: Int. J. Tuberc. Lung Dis.
– volume: 48
  start-page: 1411
  year: 2016
  ident: 33825_CR27
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.00510-2016
– volume: 55
  start-page: 1650
  year: 2017
  ident: 33825_CR37
  publication-title: J. Clin. Microbiol.
  doi: 10.1128/JCM.02498-16
– volume: 8
  start-page: 6568
  year: 2016
  ident: 33825_CR6
  publication-title: Infect. Dis. Rep.
  doi: 10.4081/idr.2016.6568
– volume: 211
  start-page: S29
  issue: Suppl 2
  year: 2015
  ident: 33825_CR7
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiu821
– volume: 47
  start-page: 1587
  year: 2016
  ident: 33825_CR26
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.02033-2015
– ident: 33825_CR1
– volume: 108
  start-page: 136
  year: 2018
  ident: 33825_CR35
  publication-title: Tuberculosis (Edinb)
  doi: 10.1016/j.tube.2017.11.014
– volume: 86
  start-page: 169
  year: 2016
  ident: 33825_CR9
  publication-title: Diagn. Microbiol. Infect. Dis.
  doi: 10.1016/j.diagmicrobio.2016.06.007
– volume: 13
  start-page: e0193589
  year: 2018
  ident: 33825_CR16
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0193589
– volume: 198
  start-page: 33
  year: 2018
  ident: 33825_CR22
  publication-title: Immunol. Lett.
  doi: 10.1016/j.imlet.2018.04.001
– volume: 73
  start-page: 588
  year: 2016
  ident: 33825_CR28
  publication-title: J. Infect.
  doi: 10.1016/j.jinf.2016.09.008
– volume: 23
  start-page: 455
  year: 2018
  ident: 33825_CR5
  publication-title: Respirology
  doi: 10.1111/resp.13272
– volume: 185
  start-page: 206
  year: 2012
  ident: 33825_CR24
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/rccm.201107-1355OC
– volume: 46
  start-page: 1838
  year: 2015
  ident: 33825_CR2
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.01179-2015
– volume: 200
  start-page: 3008
  year: 2018
  ident: 33825_CR14
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1701737
– volume: 66
  start-page: 475
  year: 2013
  ident: 33825_CR12
  publication-title: J. Infect.
  doi: 10.1016/j.jinf.2013.02.004
– volume: 49
  start-page: 1601976
  issue: 3
  year: 2017
  ident: 33825_CR36
  publication-title: European Respiratory Journal
  doi: 10.1183/13993003.01976-2016
– volume: 168
  start-page: 1346
  year: 2003
  ident: 33825_CR21
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/rccm.200306-837OC
– volume: 43
  start-page: 1568
  year: 2013
  ident: 33825_CR25
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201243262
– volume: 69
  start-page: 533
  year: 2014
  ident: 33825_CR23
  publication-title: J. Infect.
  doi: 10.1016/j.jinf.2014.06.009
– volume: 24
  start-page: 110
  year: 2018
  ident: 33825_CR15
  publication-title: J. Infect. Chemother.
  doi: 10.1016/j.jiac.2017.09.012
– volume: 45
  start-page: 928
  year: 2015
  ident: 33825_CR4
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00214014
– volume: 59
  start-page: 1
  year: 2010
  ident: 33825_CR31
  publication-title: MMWR Recomm Rep.
– volume: 12
  start-page: e0183846
  year: 2017
  ident: 33825_CR8
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0183846
– volume: 48
  start-page: 1751
  year: 2016
  ident: 33825_CR13
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.01012-2016
– ident: 33825_CR30
– volume: 187
  start-page: 2222
  year: 2011
  ident: 33825_CR19
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1101122
– volume: 9
  start-page: e94949
  year: 2014
  ident: 33825_CR20
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0094949
– volume: 51
  start-page: 1800153
  issue: 3
  year: 2018
  ident: 33825_CR18
  publication-title: European Respiratory Journal
  doi: 10.1183/13993003.00153-2018
– volume: 20
  start-page: 1554
  year: 2016
  ident: 33825_CR10
  publication-title: Int. J. Tuberc. Lung Dis.
  doi: 10.5588/ijtld.16.0342
– volume: 2015
  start-page: 589471
  year: 2015
  ident: 33825_CR11
  publication-title: Biomed. Res. Int.
  doi: 10.1155/2015/589471
– volume: 196
  start-page: 638
  year: 2017
  ident: 33825_CR32
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/rccm.201704-0817OC
– reference: 26405286 - Eur Respir J. 2015 Dec;46(6):1563-76
– reference: 27431433 - Diagn Microbiol Infect Dis. 2016 Oct;86(2):169-71
– reference: 27717779 - J Infect. 2016 Dec;73(6):588-597
– reference: 27836953 - Eur Respir J. 2016 Dec;48(6):1751-1763
– reference: 29054459 - J Infect Chemother. 2018 Feb;24(2):110-116
– reference: 27390280 - Eur Respir J. 2016 Nov;48(5):1411-1419
– reference: 27776600 - Int J Tuberc Lung Dis. 2016 Nov;20(11):1554-1561
– reference: 29523314 - Tuberculosis (Edinb). 2018 Jan;108:136-142
– reference: 29457312 - Respirology. 2018 May;23(5):455-466
– reference: 28802403 - Tuberculosis (Edinb). 2017 Sep;106:38-43
– reference: 29617458 - PLoS One. 2018 Apr 4;13(4):e0193589
– reference: 25765104 - J Infect Dis. 2015 Apr 1;211 Suppl 2:S29-38
– reference: 29567725 - Eur Respir J. 2018 Mar 22;51(3):null
– reference: 26621888 - Eur Respir J. 2015 Dec;46(6):1838-9
– reference: 27403267 - Infect Dis Rep. 2016 Jun 24;8(2):6568
– reference: 23103734 - Am J Respir Crit Care Med. 2013 Jan 15;187(2):206-11
– reference: 28298455 - J Clin Microbiol. 2017 Jun;55(6):1650-1657
– reference: 26869677 - Eur Respir J. 2016 May;47(5):1587-90
– reference: 20577159 - MMWR Recomm Rep. 2010 Jun 25;59(RR-5):1-25
– reference: 26346028 - Biomed Res Int. 2015;2015:589471
– reference: 29635002 - Immunol Lett. 2018 Jun;198:33-43
– reference: 28737960 - Am J Respir Crit Care Med. 2017 Sep 1;196(5):638-648
– reference: 28331040 - Eur Respir J. 2017 Mar 22;49(3):
– reference: 12969871 - Am J Respir Crit Care Med. 2003 Dec 1;168(11):1346-52
– reference: 24975174 - J Infect. 2014 Dec;69(6):533-45
– reference: 23456989 - Eur J Immunol. 2013 Jun;43(6):1568-77
– reference: 25792630 - Eur Respir J. 2015 Apr;45(4):928-52
– reference: 23462597 - J Infect. 2013 Jun;66(6):475-86
– reference: 19105884 - Int J Tuberc Lung Dis. 2009 Jan;13(1):84-92
– reference: 25362202 - Clin Infect Dis. 2015 Feb 1;60(3):432-7
– reference: 24740417 - PLoS One. 2014 Apr 16;9(4):e94949
– reference: 22071329 - Am J Respir Crit Care Med. 2012 Jan 15;185(2):206-12
– reference: 21775682 - J Immunol. 2011 Sep 1;187(5):2222-32
– reference: 29540577 - J Immunol. 2018 Apr 15;200(8):3008-3019
– reference: 28837654 - PLoS One. 2017 Aug 24;12(8):e0183846
SSID ssj0000529419
Score 2.3794224
Snippet Lack of biomarkers for treatment monitoring is listed among the main requirements for next generation assays, as identified globally among tuberculosis (TB)...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 15626
SubjectTerms 13
13/21
631/250/255/1856
692/308/575
Antigens
Diagnosis
Humanities and Social Sciences
multidisciplinary
Patients
Peptides
Science
Science (multidisciplinary)
Tuberculosis
γ-Interferon
Title Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection
URI https://link.springer.com/article/10.1038/s41598-018-33825-w
https://www.ncbi.nlm.nih.gov/pubmed/30353115
https://www.proquest.com/docview/2124454153
https://www.proquest.com/docview/2125310456
https://pubmed.ncbi.nlm.nih.gov/PMC6199315
Volume 8
WOSCitedRecordID wos000448049400023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M7P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: BENPR
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Health & Medical Collection
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: 7X7
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: PIMPY
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Science Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M2P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/sciencejournals
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LbtQwcERbkLjwfgTKykjcIGoSJ7H3hAC1gkNXAYG0nCLbsdWVVk7Jg6p_z9h5VEtFL-Tgi-0k1sx43jMAbwSraCRyFyUudYgSeBaKSiC5J4blFXKgXKa-2QRbrfh6vSxGg1s7hlVOd6K_qKtaORv5UeIYUYbshr4__xW6rlHOuzq20NiDA1clgfrQvWK2sTgvVhovx1yZiPKjFl_gcspiHqJulmThxS4_uiZkXo-V_Mth6vnQyf3_PcEDuDdKoOTDgDIP4Za2j-DO0JPy8jGcDfWMSW3IkJt1SWpLvvbCRRXpprZhse1b0gyxtZpsLBlrs7bEGXWJ8DcoEbYiWxRkbUe6XupG9du63bRkiv6yT-DHyfH3T5_DsR1DqFKWdqFITWpQmeaKqSTXFY-40CzlMU0ziU_CZOYSvkXOE6OYYWppUtSmUKZQNI8EfQr7trb6ORDUezTLJY2pjNMqjuTSKGlyzg0iFNcygHgCSqnGWuWuZca29D5zyssBkCUCsvSALC8CeDvvOR8qddy4-nACUjlSbVteQSiA1_M00ptzogir696vwWvLCcIBPBtQY_4cigOZq14UANtBmnmBq-W9O2M3Z76md-4CKd3OdxN6Xf3Wv0_x4uZTvIS7iUN1ZLUJPYT9run1K7itfnebtlnAHlszP_IFHHw8XhXfFt4kgeNpUiw8LeFM8eW0-PkHgFAk0w
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VAoILb0qggJHgBFETx4m9B4QQULVqWS1SkXpLHcdRV1o5bR6s9k_xGxk7j2qp6K0Hco3zcPLNy_5mBuCt5HkUyMSyxDPtowce-zKXKO604EmOFijJmGs2wadTcXw8mW3A7yEXxtIqB53oFHVeKrtGvkOtIYrR3ESfzs592zXK7q4OLTQ6WBzo1RJDtvrj_lf8v-8o3f129GXP77sK-Ipx1viSFazAmFAormiicxEIqTkTYcTiDA_Ks9jmLctE0ELxgqtJwTAoQNOooiSQEd73BtxEN4IKRxWcjWs6dteMhZM-NyeIxE6NL2xz2ELhYyxIY3-5bv8uObWXuZl_bdA6u7d7_3_7Yg_gXu9hk8-dSDyEDW0ewe2u5-bqMZx29ZpJWZAu92xFSkN-tNKypnRVGn-2aGtSddxhTeaG9LVna2IXrYl0FoJIk5MFOuqmIU2b6Uq1i7Ke12Rgt5kn8PNapvkUNk1p9DMgGNdpnmRRGGUhy8MgmxQqKxIhChQYoTMPwgEEqeprsduWIIvUcQIikXbASRE4qQNOuvTg_XjNWVeJ5MrR2wMo0l4r1ekFIjx4M55GfWI3iaTRZevGoFq2jr4HWx0Ux8ehuxPb6kwe8DWQjgNsrfL1M2Z-6mqWJ5Yoaq_8MMD54rX-PYvnV8_iNdzZO_p-mB7uTw9ewF1qxQzdChptw2ZTtfol3FK_mnldvXJySuDkumH-BwSVeaQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qZREXdkqggJHgBNFkcWLPASFEGVEVjQYJpN6C7djqSCOnzcJo_hq_juds1VDRWw_kGmdx8r3N_t57AK8Fy-NApI4lLrWPHnjii1yguEeGpTlaoFTSttkEm8_58fF0sQO_h1wYR6scdGKrqPNCuTXySeQMUYLmJp6YnhaxOJh9OD3zXQcpt9M6tNPoIHKkN2sM36r3hwf4r99E0ezz909f_L7DgK8oo7UvqKEG40OumIpSnfOAC80oD2OaSDwiJhOXwyxSHhnFDFNTQzFAQDOp4jQQMd73Glxnrmh5SxtcjOs7bgeNhtM-TyeI-aTCl3f5bCH3MS6MEn-9bQsvOLgXeZp_bda2NnB293_-evfgTu95k4-dqNyHHW0fwM2uF-fmIZx0dZxJYUiXk7YhhSXfGuHYVLosrL9YNRUpO06xJktL-pq0FXGL2US0loMIm5MVOvC2JnUjdamaVVEtKzKw3uwj-HEl03wMu7aw-gkQjPc0S2UcxjKkeRjIqVHSpJwbFCSupQfhAIhM9TXaXauQVdZyBWKedSDKEERZC6Js7cHb8ZrTrkLJpaP3B4BkvbaqsnN0ePBqPI16xm0eCauLph2D6toFAB7sdbAcH4duUOKqNnnAtgA7DnA1zLfP2OVJW8s8dQRSd-W7Adrnr_XvWTy9fBYv4RaiO_t6OD96BrcjJ3HobUTxPuzWZaOfww31q15W5YtWZAn8vGqU_wH5moJh
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+therapy+on+Quantiferon-Plus+response+in+patients+with+active+and+latent+tuberculosis+infection&rft.jtitle=Scientific+reports&rft.au=Petruccioli%2C+Elisa&rft.au=Chiacchio%2C+Teresa&rft.au=Vanini%2C+Valentina&rft.au=Cuzzi%2C+Gilda&rft.date=2018-10-23&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=8&rft_id=info:doi/10.1038%2Fs41598-018-33825-w&rft_id=info%3Apmid%2F30353115&rft.externalDocID=PMC6199315
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon